On August 23, the 2022 Fortune China ESG Impact List was announced, with 40 companies on the list.Fosun Pharma topped the list for its remarkable achievements in environmental, social, and corporate governance (ESG) and positive contributions in the fight against the COVID-19 pandemic.

The 2022 Fortune China ESG Impact List was produced by the editorial team of Fortune magazine, after it opened up this year's application to a wide range of Chinese companies, which were invited to fill out data questionnaires and submit case studies. After fully considering the performance of the company applicants in the three dimensions of Environmental, Social and Governance, as well as the influence of the industry and their ESG scores, 40 companies were finally selected to be on the list this year. Since different industries face various ESG issues, the editorial team follows two principles in making the list. First, data and cases are of equal importance, and the completeness of data submission is the key factor in list making. Second, priority is given to intra-industry comparisons on issues that are highly relevant to the industry, and then make cross-industry comparisons.

The Fortune editorial team commented, "We look for companies that are committed to leading the world back to safety and prosperity by better embracing environmental, social and governance responsibilities while creating wealth.The 40 Chinese companies on the list have made outstanding efforts to improve the environment, protect their employees and support their communities. Their pursuit of values that transcend financial metrics with warmth is reshaping our definition of good business."

Fosun Pharma (Stock Code: 600196.SH, 02196.HK) was established in 1994 and listed on the main board of the Hong Kong Stock Exchange in 2012. As a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China, Fosun Pharma has been actively promoting ESG management and information disclosure, continuously improving the company's ESG system, and helping the company's long-term sustainable development. Fosun Pharma has released Social Responsibility Reports for 14 consecutive years. The "2021 Corporate Social Responsibility Report" won a five-star rating (excellent) by China CSR Report Rating Expert Committee. Fosun Pharma also won the 2020 "Benefiting the Future" China Corporate Responsibility Social Contribution Award, 2020 Anti-epidemic Contribution Award, "Outstanding Enterprise in Scientific and Technological Innovation" selected by "China Benefit Company" for corporate social responsibility. Fosun Pharma has disclosed the ESG (Environmental, Social and Governance) report within its annual report for two consecutive years, continuously demonstrating the Company's ESG performance to stakeholders. Fosun Pharma’s MSCI ESG rating of Fosun Pharma was BBB and it’s WIND ESG rating was AA level. The Company also won the top 500 ESG Enterprises in China and has been selected in the "Technology Responsibility Pioneer 30 Index" in 2022.

Since the outbreak of the COVID-19 pandemic, Fosun Pharma has responded quickly. The Company has made use of its global layout and scientific research and innovation capabilities accumulated over the years, promoting the creation of an innovative product matrix from prevention, and detection to treatment, fighting the pandemic with the power of science and technology, and actively fulfilling the corporate social responsibility. Developed by Fosun Pharma and Germany's BioNTech, the mRNA COVID-19 vaccine COMIRNATY^® (mRNA COVID-19 vaccine, also known as BNT162b2) was included in the Hong Kong and Macau government vaccination plan in March 2021 and began to be vaccinated in Taiwan region in September 2021. By the end of March 2022, more than 24 million doses of BNT162b2 have been vaccinated in Hong Kong SAR, Macau SAR and Taiwan region, helping to establish the local COVID-19 immune barrier.

***

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, oncolytic viruses, gene therapy and PROTAC, to enhance its innovation capabilities.

Guided by the 4IN strategy (Innovation, Internationalization, Integration, and Intelligentization), Fosun Pharma will uphold the development model of “innovation transformation, integrated operation, and steady growth", with the mission of creating shareholder values as well as promoting the global networks through strengthening its innovative R&D and in-licensing ability and enriching its product pipelines. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global medical and health market.

For more information, please visit our official website: www.fosunpharma.com.